Data-Gouv-ML/pcri-informations-sur-les-projets-laureats huggingface dataset:
DistributEd Chemicals And fuels production from CO2 in photoelectrocatalytic DEvices (DECADE)

Framework: Horizon 2020 — Industrial Leadership
Programme: Nanotechnologies, Advanced Materials, Advanced Manufacturing and Processing, and Biotechnology
Theme: Advanced materials
Action type: Research and Innovation actions
Countries involved: Italy,Italy,Italy,Germany,Germany,Spain,Spain,Italy,Italy,Switzerland,Greece,Türkiye,Belgium,Japan
Call: Photocatalytic synthesis (RIA) (H2020-NMBP-ST-IND-2019, 2019)
Start date: 2020-05-01
End date: 2024-10-31
Duration (months): 54.0
Total project cost (EUR): 5358672.49
EU funding (EUR): 5198756.6899999995
Participants: 17
Project status: SIGNED

DECADE project proposes a new photoelectrocatalytic (PEC) approach for the conversion of CO2 avoiding water oxidation as anodic reaction to overcome the current limits in PEC system and to maximize effective energy utilization. Novel PEC technology will be developed up to TRL 5 (prototype testing under environmental relevant conditions) using alcohols and waste CO2 as feed. Different applications are investigated: green refinery, distributed green solvent production and use to lower carbon footprint in methanol plant. In the main application, bioethanol and waste CO2 are used to produce a mixture of ethyl acetate (EA) and ethyl formate (EF) in ethanol, to be used as drop-in green solvent or as octane booster fuel component. The net impact is to produce valuable added-value products through an energy-efficient PEC device, to lower the carbon footprint by using waste CO2 and introducing renewable energy in the production chain. DECADE project will develop the PEC concept and validate at prototype unit for distributed production (productivity > 1 g/h of EA and > 1A current density per single 10x10 cm module). Optimization and engineering of electrode/materials and of the PEC design is driven by techno-economic, LCA, market & social assessments. There are several elements of innovation in the proposed DECADE approach, based on the identification of the critical issues in the current PEC design. The project is organized around three main areas: i) advances in materials and technology, with a series of novel concepts and materials proposed (TRL 3 -> 4), ii) upscaling and prototype design & manufacture (TRL 4 -> 5), focused at improving performances, stability and reduce costs, and iii) process validation by using the prototype (TRL 5). Consortium partnership has a strong industrial character, but comprises top level scientists in the area and international collaboration with Japan to allow the best possible benchmarking for the novel approach developed.

Keywords: photoelectrocatalytic,ethanol,distributed production,ethyl acetate
Discovering novel antibodies derived from the human body itself to treat neurodegenerative diseases (HominAb)

Framework: Horizon 2020 — Industrial Leadership
Programme: Innovation in SMEs
Action type: SME instrument
Countries involved: Switzerland
Call: SME instrument (H2020-SMEInst-2018-2020-1, 2019)
Start date: 2019-12-01
End date: 2020-05-31
Duration (months): 6.0
Total project cost (EUR): 71429.0
EU funding (EUR): 50000.0
Participants: 1
Project status: CLOSED

Neurodegenerative diseases are one of the disease fields with the highest unmet need. Decades of research have been invested in finding cures, however almost none have been successful. Antibodies have great therapeutic potential to treat these diseases as they are broadly applicable to specifically target different aspects of disease-causing processes. However, most of current non-human antibodies are limited by side-effects and a lack of specificity. Human-derived antibodies, derived from human blood samples, provide a solution for these limitations. They are naturally designed by the human immune system to fight toxic moieties with higher efficacy and specificity and are expected to have lower side-effects when compared to antibodies of non-human origin. However a large amount of blood samples is required to identify the rarest and most specific antibodies. Mabylon is a biotechnology company that capitalizes on the human body’s own protective capability to generate antibodies against human disease. Mabylon’s unique screening platform allows identification of a “needle in the haystack” and develop fully human antibodies for diseases with high unmet medical need in the field of allergies and neurodegenerative diseases. Mabylon is currently developing several antibodies including an antibody for TDP-43, a toxic protein associated with diseases progression in ALS and FTD. ALS as a potential initial market could generate €110M in licensing revenue in 2021-2025 and €170M in royalties (5%) from 2026-2030. In addition, platform expansion towards other indications addresses a total neurodegenerative drug market worth €40B by 2022. In the HominAb project, we will investigate our market positioning, the commercial landscape, preclinical development and licensing strategy in order to enable successful commercial maturation of our platform for neurodegenerative diseases.

Keywords: drug development,human derived antibodies,drug discovery platform,amyotrophic lateral sclerosis,frontotemporal dementia,neurodegeneration,ageing,therapeutic antibody
Technology and hardware for neuromorphic computing (TEMPO)

Framework: Horizon 2020 — Industrial Leadership
Programme: Information and Communication Technologies
Theme: Public-private partnerships
Destination: Electronic Components and Systems
Action type: Research and Innovation actions
Partnership: ECSEL (Art-187)
Countries involved: Germany,Germany,Germany,Germany,Germany,Germany,Germany,Germany,Switzerland,Belgium,France,France,France,France,Netherlands
Call: H2020-ECSEL-2018-2-RIA (H2020-ECSEL-2018-2-RIA-two-stage-1, 2018)
Start date: 2019-05-01
End date: 2023-01-31
Duration (months): 45.0
Total project cost (EUR): 34018428.98
EU funding (EUR): 10158197.709999999
Participants: 21
Project status: SIGNED

Massive adoption of computing in all aspects of human activity has led to unprecedented growth in the amount of data generated. Machine learning has been employed to classify and infer patterns from this abundance of raw data, at various levels of abstraction. Among the algorithms used, brain-inspired, or “neuromorphic”, computation provides a wide range of classification and/or prediction tools. Additionally, certain implementations come about with a significant promise of energy efficiency: highly optimized Deep Neural Network (DNN) engines, ranging up to the efficiency promise of exploratory Spiking Neural Networks (SNN). Given the slowdown of silicon-only scaling, it is important to extend the roadmap of neuromorphic implementations by leveraging fitting technology innovations. Along these lines, the current project aims to sweep technology options, covering emerging memories and 3D integration, and attempt to pair them with contemporary (DNN) and exploratory (SNN) neuromorphic computing paradigms. The process- and design-compatibility of each technology option will be assessed with respect to established integration practices. Core computational kernels of such DNN/SNN algorithms (e.g. dot-product/integrate-and-fire engines) will be reduced to practice in representative demonstrators.

Keywords: application specific integrated circuit asic,classification,deep neural networks,interference,mram,non volatile memory,oxram,spiking neural networks
MAssive intracellular REcording for Pharmacology (MAREP)

Framework: Horizon 2020 — Excellent Science
Programme: European Research Council (ERC)
Theme: European research council
Destination: Proof of concept grants
Action type: ERC actions
Panel: Condensed matter physics
Panel description: Structure, electronic properties, fluids, nanosciences, biological physics
Countries involved: Italy
Call: ERC Proof of Concept Grant (ERC-2019-PoC, 2019)
Start date: 2019-11-01
End date: 2021-04-30
Duration (months): 18.0
Total project cost (EUR): 150000.0
EU funding (EUR): 150000.0
Participants: 1
Project status: CLOSED

Due to the vital role of the heart, cardiac safety assessment has become one of the major gatekeepers in all stages of the drug development process, increasing costs and resources required for new drugs. Despite the recent advancements of the Comprehensive In vitro ProArrhythmia (CiPA) initiative, there are still important obstacles related to chronic cardiotoxicities and to unreliable cell models. Thus, there is a strong need for new solutions that can improve the efficacy of drug development processes. The MAREP project aims at tackling this problem by demonstrating a novel automated system for the comprehensive pharmacologic investigation of drug effects on in-vitro cardiac cell cultures. The novel approach combines laser excitation of novel metamaterials with high density multielectrode arrays (HD-MEA), providing high quality and high throughput recording of cardiac cells activity and offering an unprecedented and affordable method for the global study of drug effects on the heart. The outcome of the project is the prototype of a system that combines electrical recording of action potentials of thousands of cardiac cells with laser-based cell poration and intracellular recording. In essence, cardiac cells can be investigated in physiological conditions while drugs are administered and their effects studied in details on a large and reliable biological sample. The MAREP technology will boost the development of new drugs through the establishment of a novel, affordable, cost-effective and automated experimental procedure. This project intends to exploit a research innovation born, though not exploited, in the parent ERC project Neuro-plasmonics. This innovation may bring the laser-based bio-nanotechnologies developed in Neuro-plasmonics closer to commercialization by introducing a novel interface that is fully compatible with standard CMOS technology and with large scale production.

Keywords: intracellular recording,drug screening,cardiac electrophysiology,multielectrode arrays,laser cell,poration,pharmacology,toxicology
Evolution of antibiotic tolerance in the 'wild': A quantitative approach (Tolerome)

Framework: Horizon 2020 — Excellent Science
Programme: European Research Council (ERC)
Theme: European research council
Destination: Consolidator grants
Action type: ERC actions
Panel: Environmental Biology, Ecology and Evolution
Panel description: Ecology, biodiversity, environmental change, evolutionary biology, behavioural ecology, microbial ecology, marine biology, ecophysiology, theoretical developments and modelling
Countries involved: Israel
Call: ERC Consolidator Grant (ERC-2015-CoG, 2015)
Start date: 2016-05-01
End date: 2021-10-31
Duration (months): 66.0
Total project cost (EUR): 1978750.0
EU funding (EUR): 1978750.0
Participants: 1
Project status: CLOSED

Bacterial ability to evolve strategies for evading antibiotic treatment is a fascinating example of an evolutionary process, as well as a major health threat. Despite efforts to understand treatment failure, we lack the means to prevent evolution of resistance when a new drug is released to the market. Most efforts are directed towards understanding the mechanisms of antibiotic resistance. Whereas ‘resistance’ is due to mutations that enable microorganisms to grow even at high concentrations of the drug, ‘tolerance’ is the ability to sustain a transient treatment, for example by entering a mode of transient dormancy. The importance of tolerance in the clinic has not been investigated as thoroughly as resistance. The presence of tolerant bacteria is not detected in the clinic because of the inherent difficulty of tracking dormant bacteria that often constitute only a minute fraction of the bacterial population. I hypothesize that bacterial dormancy may evolve quickly in the host under antibiotic treatment. This hypothesis is strengthened by our recent results demonstrating the rapid evolution of dormancy leading to tolerance in vitro, and by the increasing number of cases of treatment failure in the clinic not explained by resistance. My goal is to develop a multidisciplinary approach to detect, quantify and characterize tolerant bacteria in the clinic. Using my background in quantitative single-cell analyses, I will develop microfluidic devices for the rapid detection of tolerant bacteria in the clinic, systems biology tools to isolate and analyze dormant sub-populations directly from clinical isolates. I will search for the genetic mutations leading to tolerance, namely build what I term here the ‘tolerome’. The results will be analyzed in a mathematical framework of tolerance evolution. This approach should reveal the role of tolerance in the clinic and may lead to a paradigm shift in the way bacterial infections are characterized and treated.

Keywords: persistence,antibiotics,infections
Specialised plant cell types via developmentally-controlled gene knockouts: a key step towards fully customised plants (GREEN-SPECIALISTS)

Framework: Horizon 2020 — Excellent Science
Programme: Marie-Sklodowska-Curie Actions
Theme: Marie Skłodowska-Curie
Destination: Individual Fellowships (IF)-Standard European Fellowships
Action type: Marie Skłodowska-Curie actions
Panel: Environment and Geosciences
Countries involved: Denmark
Call: Individual Fellowships (H2020-MSCA-IF-2016, 2016)
Start date: 2018-03-01
End date: 2020-02-29
Duration (months): 24.0
Total project cost (EUR): 200194.8
EU funding (EUR): 200194.8
Participants: 1
Project status: CLOSED

A goal of plant engineering is to produce valuable resources from CO2 and solar energy while exploiting the natural advantages of plants as production platforms. Plants have highly specialised cell types and sophisticated development programs, resulting in specialist producer cells that are supported by non-producer parts. Plants are the only organisms that combine autotrophy and extensive multicellular differentiation, yet current engineering strategies fail to fully exploit the potential advantages of plants as chemical production systems. This action proposes to develop and demonstrate a crucial technical advance in plant engineering: developmentally-programmed gene knock-outs in specialised cell types. Genetic knockout of competing metabolic pathways is essential to improving the yield of desirable metabolites. CRISPR/Cas9 gene editing in plants has been developed to the point where multiple homozygous gene knockouts can be made with high efficiency, but in all published examples the knockouts are systemic (i.e. present in every cell). I propose to introduce and validate a set of instructions that program the activation of CRISPR/Cas9 in specific cell types during plant development, resulting in gene deletions only in the targeted cells. The ability to produce chimeric plants with deliberately engineered specialist cell types is an essential step toward realising the potential of plant engineering. This action will generate intellectual property and a set of methods that will be useful to the wider plant research community. My broad experience in systems and synthetic biology and the world-class expertise of the host institution in plant biochemistry and light-driven biosynthesis are an ideal match for success in this action. Successful implementation will develop and diversify my skills while creating an ideal opportunity for independent career development, including attracting further funding and forming external collaborations.

Keywords: metabolic engineering,chimeric plants,crispr,cas9,promoters,differentiation,fluorophore,facs,arabidopsis thaliana
Improved Methods and Actionable Tools for Enhancing Health Technology Assessment (IMPACT HTA)

Framework: Horizon 2020 — Societal Challenges
Programme: Health, demographic change and wellbeing
Theme: Methods and data
Action type: Research and Innovation actions
Countries involved: Germany,Spain,Italy,Spain,Italy,Poland,Sweden,Slovenia,France,United Kingdom,Portugal,United Kingdom,United Kingdom
Call: Methods research for improved health economic evaluation (H2020-SC1-2017-Single-Stage-RTD, 2017)
Start date: 2018-01-01
End date: 2021-06-30
Duration (months): 42.0
Total project cost (EUR): 4593306.25
EU funding (EUR): 4593306.25
Participants: 15
Project status: CLOSED

IMPACT HTA proposes new and improved methods, tools and guidance for decision-makers across ten research areas in the context of HTA and health system performance measurement, which, overall, contribute to the understanding of costs and health outcomes variations within and across countries and to costs and health outcomes data integration from different sources. IMPACT HTA researches factors on the supply and demand side of health systems that have major effects on the costs and outcomes of health-related interventions. It includes methods for more robust measures of quality of life, patient preferences, patient-reported outcomes, better incorporation of stakeholder views into value assessments, developing methods for cost comparability leading to better generalisability of economic evaluations as well as measuring broader economic and societal impacts and incorporating these in economic evaluations and improvements in performance at health system and provider level. The perspectives of different stakeholder groups in the health system and the broader economy are taken into account, including patients, HTA agencies, the macro-economy, hospitals and hospital networks. These perspectives are obtained through participation in research and preference elicitation (patients, hospitals, hospital networks), or derived explicitly through participation in this consortium (HTA agencies). With respect to data integration, IMPACT HTA develops new methods to integrate data on direct and indirect costs of illness and on health outcomes from various sources, such as randomised controlled trials, observational studies and registries. New methods proposed make use of the strengths of real-world data and address their limitations. The consortium calibre in terms of research and research planning track record, continuous interaction with decision-makers and the patient community will ensure project objectives are realistic and achievable within the project’s duration.

Keywords: health technology assessment,performance measurement,real world data use,value assessment,value dimensions,costing methodology,patient preferences,fiscal impact,orphan medicinal products
Hydrophobic Gating in nanochannels: understanding single channel mechanisms for designing better nanoscale sensors (HyGate)

Framework: Horizon 2020 — Excellent Science
Programme: European Research Council (ERC)
Theme: European research council
Destination: Starting grants
Action type: ERC actions
Panel: Products and processes engineering
Panel description: Product and process design, chemical, civil, environmental, mechanical, vehicle engineering, energy processes and relevant computational methods
Countries involved: Italy
Call: ERC Starting Grant (ERC-2018-STG, 2018)
Start date: 2019-02-01
End date: 2024-01-31
Duration (months): 60.0
Total project cost (EUR): 1496250.0
EU funding (EUR): 1496250.0
Participants: 1
Project status: SIGNED

Hydrophobic gating is the phenomenon by which the flux of ions or other molecules through biological ion channels or synthetic nanopores is hindered by the formation of nanoscale bubbles. Recent studies suggest that this is a generic mechanism for the inactivation of a plethora of ion channels, which are all characterized by a strongly hydrophobic interior. The conformation, compliance, and hydrophobicity of the nanochannels – in addition to external parameters such as electric potential, pressure, presence of gases – have a dramatic influence on the probability of opening and closing of the gate. This largely unexplored confined phase transition is known to cause low frequency noise in solid-state nanopores used for DNA sequencing and sensing, limiting their applicability. In biological channels, hydrophobic gating might conspire in determining the high selectivity towards a specific ions or molecules, a characteristic which is sought for in biosensors. The objective of HyGate is to unravel the fundamental mechanisms of hydrophobic gating in model nanopores and biological ion channels and exploit their understanding in order to design biosensors with lower noise and higher selectivity. In order to achieve this ambitious goal, I will deploy the one-of-a-kind simulation and theoretical tools I developed to study vapor nucleation in extreme confinement, which comprises rare-event molecular dynamics and confined nucleation theory. These quantitative tools will be instrumental in designing better biosensors and nanodevices which avoid the formation of nanobubbles or exploit them to achieve exquisite species selectivity. The novel physical insights into the behavior of water in complex nanoconfined environments are expected to inspire radically innovative strategies for nanopore sensing and nanofluidic circuits and to promote a stepwise advancement in the fundamental understanding of hydrophobic gating mechanisms and their influence on bio-electrical cell response.

Keywords: rare events simulations,molecular dynamics,nanopore sensing,capillary evaporation,neuron models
AUTOMATIC VERTICAL SCANNER FOR DETERMING LEAN DISTRIBUTION IN ANIMAL CARCASSES (AVSCAN) (GM-SCAN)

Framework: Horizon 2020 — Societal Challenges
Programme: Food security, sustainable agriculture and forestry, marine and maritime and inland water research and the bioeconomy
Action type: SME instrument
Countries involved: Ireland
Call: Resource-efficient eco-innovative food production and processing (H2020-SMEINST-1-2014, 2014)
Start date: 2015-01-01
End date: 2015-06-30
Duration (months): 6.0
Total project cost (EUR): 71429.0
EU funding (EUR): 50000.0
Participants: 1
Project status: CLOSED

Meat industry generates an annual turnover of €203b in the EU-28, and employs 560,000 people. The slaughtering sector plays a key role within the meat industry, being represented by more than 4,500 companies, and generating a turnover of €73b. In a context of a strong market competitiveness, slaughterhouses are striving to minimize production costs and maximize the value of their raw meat products by improving their segmentation. In particular, meat processors increasingly request pre-classified products according to lean content. This demand is raising the interest of slaughterhouse industry for more accurate and reliable technologies to automatically grade animal carcasses according to the lean content in their primal cuts. Existing grading technologies in the market have limitations in terms of performance, robustness and cost. Moreover, they rely on measuring morphological parameters of the carcass to predict lean content, which makes the calibrations strongly dependent on the animal breed, and compromises the reliability of the carcass classification. Based on previous knowledge established in a former European Research Project, we aim at validating a novel carcass grading technology, which is able to accurately provide a direct measurement of the lean content in the carcass and its primal cuts, thus being independent of breed variations. The technology under development offers additional advantages over competing technologies in terms of cost, and easiness of integration. The estimated potential market for GM-SCAN is around €150M, and through our established network of customers in the sector we expect to be able to generate €13.8M after 5 years. GM-SCAN technology has been already demonstrated at pig slaughterhouses (TRL7). Through the proposed Phase I project, we aim at achieving the same stage of development for the beef application (currently at TRL6 – pilot line level), and to elaborate a business plan prior to undertaking the product development phase.

Keywords: automatic pig and beef carcass classification,electromagnetic scanner